

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1005 10051413/ BNT162b2 (30 µg)	2	204	26JUL2021	FOLLOW-UP	OTHER	Participant enrolled in C4591031
C4591001 1005 10051441/ BNT162b2 (30 µg)	2	206	05AUG2021	FOLLOW-UP	OTHER	Participant enrolled in C4591031
C4591001 1006 10061200/ Placebo	4	142	26AUG2021	FOLLOW-UP	LOST TO FOLLOW-UP	Lost to follow-up, noncompliant
C4591001 1006 10061206/ Placebo	2	147	18MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	parent requested to withdraw consent
C4591001 1006 10061207/ Placebo	2	147	18MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	participant withdrew consent
C4591001 1006 10061221/ BNT162b2 (30 µg)	2	218	02AUG2021	FOLLOW-UP	OTHER	enrolled in C4591031
C4591001 1006 10061265/ BNT162b2 (30 µg)	2	129	14MAY2021	FOLLOW-UP	NO LONGER MEETS ELIGIBILITY CRITERIA	RECEIVED COVID VACCINE OUTSIDE STUDY
C4591001 1006 10061280/ BNT162b2 (30 µg)	2	208	02AUG2021	FOLLOW-UP	OTHER	enrolled in C4591031

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1006 10061287/ Placebo	2	135	25MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Discontinued
C4591001 1006 10061288/ BNT162b2 (30 µg)	2	204	02AUG2021	FOLLOW-UP	OTHER	enrolled in C4591031
C4591001 1006 10061296/ Placebo	2	129	27MAY2021	FOLLOW-UP	LOST TO FOLLOW-UP	unable to contact
C4591001 1006 10061297/ BNT162b2 (30 µg)	2	129	27MAY2021	FOLLOW-UP	LOST TO FOLLOW-UP	unable to contact
C4591001 1007 10071593/ Placebo	1	24	20JAN2021	VACCINATION	PROTOCOL DEVIATION	receipt of non-study COVID vaccine prior to study end
	1	47	12FEB2021	FOLLOW-UP	PROTOCOL DEVIATION	Receipt of non-study COVID vaccine prior to study end
C4591001 1007 10071622/ BNT162b2 (30 µg)	1	22	20JAN2021	VACCINATION	OTHER	Participant had COVID-19 prior to second vaccine
C4591001 1007 10071635/ Placebo	2	108	12MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Pfizer vaccine outside of study, participant verbalized wanting to withdrawal from the study
C4591001 1007 10071639/ Placebo	2	128	01JUN2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	Participant Moving
C4591001 1008 10081758/	2	223	02AUG2021	FOLLOW-UP	OTHER	Participant enrolled in C4591031

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
BNT162b2 (30 µg)						
C4591001 1008 10081829/ Placebo	2	122	13MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	requested unblinding 5/12, withdrew consent 5/13
C4591001 1008 10081834/ Placebo	2	121	13MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	requested unblinding 5/12, withdrew consent 5/13
C4591001 1008 10081871/ Placebo	1	78	17MAR2021	VACCINATION	OTHER	2nd vax not given due to confirmed covid illness prior to vax #2
C4591001 1008 10081884/ Placebo	1	79	19MAR2021	VACCINATION	OTHER	2nd vax not given due to confirmed covid illness prior to vax #2
C4591001 1008 10081901/ Placebo	2	18	12FEB2021	VACCINATION	OTHER	the participant is willing/eligible to receive Vaccination 3
C4591001 1009 10091227/ BNT162b2 (30 µg)	2	259	26JUL2021	FOLLOW-UP	OTHER	Subject enrolled in C4591031 study
C4591001 1009 10091287/ BNT162b2 (30 µg)	2	225	04AUG2021	FOLLOW-UP	OTHER	Participant enrolled in C4591031
C4591001 1009 10091307/ BNT162b2 (30 µg)	2	245	31AUG2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	subject moved to Texas

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1009 10091308/ Placebo	2	245	31AUG2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	subject moved to texas
C4591001 1009 10091332/ BNT162b2 (30 µg)	2	216	02AUG2021	FOLLOW-UP	OTHER	participant enrolled in C4591031
C4591001 1009 10091338/ Placebo	1	19	01JAN2021	VACCINATION	NO LONGER MEETS ELIGIBILITY CRITERIA	exclusion #5
C4591001 1009 10091363/ Placebo	1	11	27DEC2020	VACCINATION	NO LONGER MEETS ELIGIBILITY CRITERIA	has tested positive for COVID-19
C4591001 1009 10091383/ BNT162b2 (30 µg)	2	193	05AUG2021	FOLLOW-UP	OTHER	Participant enrolled in C4591031
C4591001 1013 10131830/ Placebo	2	141	12MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	Wanted to get vaccine closer to home and now able to do so.
C4591001 1013 10131846/ BNT162b2 (30 µg)	2	144	14MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	Mother wanted unblinded did not want to continue in study; wanted vaccine in community.
C4591001 1013 10131848/ Placebo	2	144	14MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	Mother wanted unblinded did not want to continue in study; wanted vaccine in community.
C4591001 1013 10131856/ BNT162b2 (30 µg)	2	133	11MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject no longer able to make appointments due to drive.

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1013 10131862/ BNT162b2 (30 µg)	2	232	17AUG2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	SUBJECT MOVED TO SEATTLE
C4591001 1013 10131868/ Placebo	2	127	18MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject received first dose in community.
C4591001 1013 10131869/ Placebo	2	141	02JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject wanted to get vaccine closer to home.
C4591001 1013 10131870/ Placebo	2	100	22APR2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject could not make the time commitment with 2 hour drive.
C4591001 1013 10131878/ Placebo	2	133	25MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Unable to make further appointments - vaccinated in community.
C4591001 1016 10161316/ Placebo	1	17	01NOV2020	VACCINATION	NO LONGER MEETS ELIGIBILITY CRITERIA	subject with positive covid-19
C4591001 1016 10161379/ Placebo	1	30	05FEB2021	VACCINATION	NO LONGER MEETS ELIGIBILITY CRITERIA	subject with positive covid test
C4591001 1039 10391253/ BNT162b2 (30 µg)	2	225	09AUG2021	FOLLOW-UP	LOST TO FOLLOW-UP	Subject lost to follow up
C4591001 1039 10391264/ Placebo	3	16	08JUN2021	OPEN LABEL TREATMENT	WITHDRAWAL BY SUBJECT	Subject has withdrawn from study.
	3	16	08JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject has withdrawn from study.

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1039 10391332/ BNT162b2 (30 µg)	2	129	10JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject has withdrawn consent.
C4591001 1044 10441289/ Placebo	2	220	18AUG2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	withdrew consent
C4591001 1044 10441293/ Placebo	3	39	21JUN2021	OPEN LABEL TREATMENT	PROTOCOL DEVIATION	subject received dose outside of study
C4591001 1044 10441294/ Placebo	3	50	02JUL2021	OPEN LABEL TREATMENT	PROTOCOL DEVIATION	subject received dose outside of study
C4591001 1044 10441322/ BNT162b2 (30 µg)	2	46	13MAR2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Refused further follow-up
C4591001 1044 10441344/ Placebo	2	11	08FEB2021	VACCINATION	OTHER	transitioning to open label
C4591001 1044 10441347/ Placebo	2	120	28MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Parent/guardian contacted the site to advise that her daughter is no longer interested in continuing
C4591001 1044 10441371/ Placebo	2	183	03AUG2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	subject moved from area
C4591001 1044 10441372/ BNT162b2 (30 µg)	2	183	03AUG2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	subject moved from area

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1057 10571377/ Placebo	2	241	25AUG2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	UNABLE TO DRIVE TO JACKSONVILLE FOR STUDY VISITS
C4591001 1057 10571378/ BNT162b2 (30 µg)	2	241	25AUG2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	UNABLE TO DRIVE TO JACKSONVILLE FOR STUDY VISITS
C4591001 1057 10571385/ BNT162b2 (30 µg)	2	207	22JUL2021	FOLLOW-UP	OTHER	ENROLLED INTO C4591031
C4591001 1057 10571390/ BNT162b2 (30 µg)	2	215	30JUL2021	FOLLOW-UP	OTHER	PARTICIPANT ENROLLED INTO C4591031
C4591001 1057 10571392/ BNT162b2 (30 µg)	2	207	22JUL2021	FOLLOW-UP	OTHER	ENROLLED INTO C4591031
C4591001 1057 10571413/ BNT162b2 (30 µg)			21DEC2020	VACCINATION	NO LONGER MEETS ELIGIBILITY CRITERIA	DELAY CRITERIA MET
			21DEC2020	FOLLOW-UP	NO LONGER MEETS ELIGIBILITY CRITERIA	DELAY CRITERIA MET
C4591001 1057 10571414/ Placebo	2	148	08JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	subject no longer wants to participate
C4591001 1057 10571418/	2	229	27AUG2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	father stated just didn't want daughter participating at this time. no other reason disclosed

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
BNT162b2 (30 µg)						
C4591001 1057 10571420/ Placebo	2	45	24FEB2021	VACCINATION	WITHDRAWAL BY PARENT/GUARDIAN	mother stated she didn't want him to do it anymore
	2	45	24FEB2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	mother stated she didn't want him to do it anymore
C4591001 1057 10571421/ Placebo	2	180	09JUL2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1057 10571425/ Placebo	2	185	15JUL2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	NO LONGER WISHES TO PARTICIPATE
C4591001 1057 10571426/ BNT162b2 (30 µg)	2	194	02AUG2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	UNABLE TO COME IN FOR STUDY VISIT
C4591001 1057 10571446/ Placebo	2	213	01SEP2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	no longer interested
C4591001 1057 10571450/ Placebo	2	206	26AUG2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	no longer interested in revax V101, no longer interested in study participation
C4591001 1066 10661408/ BNT162b2 (30 µg)	2	218	02AUG2021	FOLLOW-UP	OTHER	Subject enrolled in C4591031
C4591001 1066 10661428/ Placebo	2	17	11FEB2021	VACCINATION	OTHER	subject unblinded for vax 3 per protocol



**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1066 10661431/ BNT162b2 (30 µg)	2	183	28JUL2021	FOLLOW-UP	OTHER	subject enrolled in C4591031
C4591001 1077 10771282/ Placebo	2	133	17MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	Subject recieved covid-19 vaccine outside study and is moving. Does not wish to continue in followup
C4591001 1077 10771289/ Placebo	2	127	14MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1077 10771290/ Placebo	2	127	14MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1077 10771292/ BNT162b2 (30 µg)	2	133	18MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1077 10771293/ Placebo			18DEC2020	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject withdrew consent prior to blood draw.
C4591001 1084 10841542/ Placebo	2	184	01JUL2021	FOLLOW-UP	NO LONGER MEETS ELIGIBILITY CRITERIA	subject received vaccine outside of study.
C4591001 1084 10841557/ Placebo	2	116	13MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1084 10841568/ Placebo	2	149	15JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	subject drop to due summer activities

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1084 10841579/ Placebo	2	118	24MAY2021	FOLLOW-UP	NO LONGER MEETS ELIGIBILITY CRITERIA	Subject received outside Pfizer Vaccine 14May2021
C4591001 1091 10911409/ Placebo	2	150	26MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1091 10911451/ BNT162b2 (30 µg)			04JAN2021	FOLLOW-UP	OTHER	Subject was rescreened under #1462. Subject randomized in error.
C4591001 1123 11231422/ Placebo	2	171	09JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Patient moved from the area and cannot be present for scheduled visits
C4591001 1123 11231434/ Placebo	2	137	13MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Pt requested to be dropped from the study and refused to elaborate
C4591001 1123 11231438/ Placebo	2	161	15JUN2021	FOLLOW-UP	LOST TO FOLLOW-UP	Could not reach patient via telephone to schedule vaccination
C4591001 1123 11231441/ Placebo	2	127	10MAY2021	FOLLOW-UP	LOST TO FOLLOW-UP	Patient lost to follow up due to inability to be present for appointments.
C4591001 1123 11231443/ BNT162b2 (30 µg)	2	184	06JUL2021	FOLLOW-UP	LOST TO FOLLOW-UP	Subject no-showed for V4, and site staff was unable to contact them to reschedule
C4591001 1123 11231445/ Placebo	2	163	10JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Patient requested to be out of the study, did not want to participate in crossover.
C4591001 1123 11231446/	2	183	30JUN2021	FOLLOW-UP	LOST TO FOLLOW-UP	Subject no showed for V4, staff could not contact subject

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
BNT162b2 (30 µg)						
C4591001 1123 11231448/ Placebo	2	112	20APR2021	FOLLOW-UP	LOST TO FOLLOW-UP	Inability to contact patient regarding reported symptoms on illness diary
C4591001 1123 11231478/ Placebo	2	150	09JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Patient did not want to participate in the crossover and requested to be dropped from the study.
C4591001 1123 11231479/ Placebo	2	124	14MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Patient requested to be dropped because they did not want to come into clinic for any more visits
C4591001 1123 11231483/ Placebo	2	151	10JUN2021	FOLLOW-UP	LOST TO FOLLOW-UP	Can't reach patient to schedule V101
C4591001 1123 11231486/ BNT162b2 (30 µg)	2	192	21JUL2021	FOLLOW-UP	LOST TO FOLLOW-UP	No Show for V4, can't reach subject
C4591001 1123 11231491/ Placebo	2	150	09JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject no longer wanted to participate in the crossover
C4591001 1123 11231511/ BNT162b2 (30 µg)	2	112	10MAY2021	FOLLOW-UP	LOST TO FOLLOW-UP	Could not reach patient via telephone
C4591001 1123 11231512/ BNT162b2 (30 µg)	2	112	10MAY2021	FOLLOW-UP	LOST TO FOLLOW-UP	Couldn't reach patient via telephone.

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1123 11231515/ Placebo	2	131	28MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject requested withdrawal from study due to fears of blood collection.
C4591001 1123 11231526/ Placebo	3	37	30JUN2021	FOLLOW-UP	LOST TO FOLLOW-UP	Patient consistently no-showed for V102.
C4591001 1124 11241236/ Placebo	2	149	01JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	OUT OF COUNTRY
C4591001 1124 11241242/ Placebo	2	168	21JUN2021	FOLLOW-UP	LOST TO FOLLOW-UP	Patient is Lost toFollow-up as of June 21, 2021
C4591001 1124 11241256/ Placebo	2	129	21MAY2021	FOLLOW-UP	LOST TO FOLLOW-UP	Multiple phone attempts made, certified letter sent. Subject did not complete Visit 101
C4591001 1124 11241261/ BNT162b2 (30 µg)	2	162	23JUN2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject does not wish to continue in study
C4591001 1124 11241262/ BNT162b2 (30 µg)	2	180	09JUL2021	FOLLOW-UP	LOST TO FOLLOW-UP	Several voicemails left and Certified letter sent on 7/9
C4591001 1125 11251255/ BNT162b2 (30 µg)	2	181	26JUL2021	FOLLOW-UP	LOST TO FOLLOW-UP	Certified letter sent after multiple attempts to contact for potential revax contact
C4591001 1126 11261287/ Placebo	1	15	30DEC2020	VACCINATION	NO LONGER MEETS ELIGIBILITY CRITERIA	Subject did not receive 2nd vaccine due to Covid 19 disease.

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1131 11311302/ BNT162b2 (30 µg)	2	186	05AUG2021	FOLLOW-UP	OTHER	participant enrolled in C4591031
C4591001 1139 11391189/ Placebo	2	123	13MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject's decided to withdraw and receive vaccine elsewhere
C4591001 1139 11391201/ BNT162b2 (30 µg)	2	205	04AUG2021	FOLLOW-UP	OTHER	Participant enrolled in C4591031
C4591001 1139 11391203/ Placebo	3	22	27APR2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject decided to receive 2nd dose elsewhere and wanted to withdraw.
C4591001 1139 11391235/ Placebo	3	1	15FEB2021	VACCINATION	OTHER	Crossed over to Visit 101
C4591001 1139 11391261/ BNT162b2 (30 µg)	2	183	03AUG2021	FOLLOW-UP	OTHER	Participant enrolled in C4591031
C4591001 1139 11391262/ BNT162b2 (30 µg)	2	182	04AUG2021	FOLLOW-UP	OTHER	Participant enrolled in C4591031
C4591001 1139 11391263/ Placebo	3	1	19FEB2021	VACCINATION	OTHER	Crossed-over
C4591001 1140 11401346/			22DEC2020	FOLLOW-UP	NO LONGER MEETS ELIGIBILITY CRITERIA	SUBJECT TO BE DISCONTINUED DUE TO UNABLE TO OBTAIN SPECIMEN

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
BNT162b2 (30 µg)						
C4591001 1140 11401350/ BNT162b2 (30 µg)	2	182	13JUL2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1140 11401352/ BNT162b2 (30 µg)	2	182	13JUL2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1140 11401357/ Placebo	2	124	14MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1140 11401386/ BNT162b2 (30 µg)	2	187	01AUG2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1142 11421333/ Placebo	2	217	11AUG2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	Subject withdrawn due to move
C4591001 1147 11471280/ Placebo	1	50	22FEB2021	VACCINATION	NO LONGER MEETS ELIGIBILITY CRITERIA	Treatment discontinued due to COVID Illness "exclusion 5"
C4591001 1147 11471327/ BNT162b2 (30 µg)	1	4	08JAN2021	VACCINATION	ADVERSE EVENT	ADVERSE EVENT/PYREXIA
C4591001 1150 11501199/ Placebo	2	141	19MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject does not want to complete mandatory nasal swabs required at revaccination visits 101 and 102

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1152 11521635/ BNT162b2 (30 µg)	2	185	30JUN2021	FOLLOW-UP	PROTOCOL DEVIATION	Subject no longer willing to comply with study requirements.
C4591001 1152 11521640/ BNT162b2 (30 µg)	2	150	26MAY2021	FOLLOW-UP	OTHER	Subject moved out of state. Pfizer could not provide transfer site.
C4591001 1152 11521641/ BNT162b2 (30 µg)	1	54	29JAN2021	VACCINATION	PHYSICIAN DECISION	PHYSICIAN DECISION
	1	171	26MAY2021	FOLLOW-UP	OTHER	Subject moved out of state. Pfizer could not provide transfer site.
C4591001 1152 11521650/ BNT162b2 (30 µg)	2	218	02AUG2021	FOLLOW-UP	OTHER	To participate in the C4591031 Booster Study
C4591001 1152 11521698/ Placebo	2	131	18MAY2021	FOLLOW-UP	PROTOCOL DEVIATION	Received nonstudy COVID-19 Vaccine
C4591001 1152 11521726/ Placebo	2	149	15JUN2021	FOLLOW-UP	PROTOCOL DEVIATION	Received nonstudy COVID-19 vaccine, withdrawn from study.
C4591001 1152 11521747/ Placebo	3	68	26JUL2021	FOLLOW-UP	PROTOCOL DEVIATION	Received nonstudy COVID-19 Vaccine
C4591001 1152 11521751/ Placebo	2	106	18MAY2021	FOLLOW-UP	PROTOCOL DEVIATION	Received nonstudy COVID-19 Vaccine

**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1152 11521754/ Placebo	2	110	21MAY2021	FOLLOW-UP	PROTOCOL DEVIATION	Received nonstudy COVID-19 Vaccine
C4591001 1156 11561316/ Placebo	2	73	10MAR2021	VACCINATION	PROTOCOL DEVIATION	SUBJECT CAN NOT BE REACHED VIA PHONE. CERTIFIED LETTER SENT. SUBJECT CONTINUES TO COMPLETE eDIARY.
	2	130	06MAY2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	WITHDRAWAL OF CONSENT.
C4591001 1156 11561320/ Placebo	2	34	25JAN2021	VACCINATION	WITHDRAWAL BY SUBJECT	SUBJECT AND FATHER STATED THAT THEY NO LONGER WISHED TO PARTICIPATE IN THE TRIAL.
	2	34	25JAN2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	SUBJECT AND FATHER STATED THAT THEY NO LONGER WISHED TO PARTICIPATE IN THE TRIAL.
C4591001 1156 11561336/ Placebo	2	149	08JUN2021	FOLLOW-UP	NO LONGER MEETS ELIGIBILITY CRITERIA	SUBJECT NO LONGER MEETS ELIGIBILITY BECAUSE THEY RECEIVED VACCINE OUTSIDE OF STUDY.
C4591001 1156 11561353/ Placebo	3	54	09JUL2021	OPEN LABEL TREATMENT	PROTOCOL DEVIATION	VACCINATED OFF SITE
C4591001 1156 11561359/ Placebo	3	48	30JUN2021	OPEN LABEL TREATMENT	PROTOCOL DEVIATION	SUBJECT WAS VACCINATED OFF SITE.
C4591001 1156 11561365/ Placebo	2	190	09AUG2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1156 11561366/ BNT162b2 (30 µg)	2	190	09AUG2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN



**16.2.1 Listing of Subjects Discontinued From Vaccination and/or From the Study –  
All Subjects 12 Through 15 Years of Age**

<b>Subject/ Vaccine Group (as Randomized)</b>	<b>Dose No.</b>	<b>Rel Day<sup>a</sup></b>	<b>Withdrawal Date</b>	<b>Study Phase</b>	<b>Withdrawal Reason</b>	<b>Comment<sup>b</sup></b>
C4591001 1156 11561368/ BNT162b2 (30 µg)	2	178	28JUL2021	FOLLOW-UP	OTHER	PARTICIPANT ENROLLED IN C4591031
C4591001 1156 11561375/ Placebo	2	107	19MAY2021	FOLLOW-UP	WITHDRAWAL BY PARENT/GUARDIAN	WITHDRAWAL BY PARENT/GUARDIAN
C4591001 1270 12701237/ Placebo	1	20	26JAN2021	VACCINATION	NO LONGER MEETS ELIGIBILITY CRITERIA	EC#55: Participant had a positive local COVID-19 test before Vx2, symptomatic with test
	3	56	13JUL2021	FOLLOW-UP	WITHDRAWAL BY SUBJECT	Subject declines to participate in further study activities.

a. Relative day (Rel Day) = date of withdrawal - date of last vaccination + 1. For a withdrawal that occurred before the date of the first study vaccination, + 1 was not added to compute relative day.

b. MedDRA (v24.0) coding dictionary applied.

PFIZER CONFIDENTIAL SDTM Creation: 05OCT2021 (17:30) Source Data: adds Table Generation: 08NOV2021 (17:11)

(Data Cutoff Date: 02SEP2021, Database Snapshot Date: 27SEP2021) Output File: ./nda2\_unblinded/C4591001\_S\_Peds/adds\_l001\_withd1\_ped6